Anti-viral Actions and Viral Dynamics in the Early Phase of Three Different Regimens of Interferon Treatment for Chronic Hepatitis C

Differences between the Twice-daily Administration of Interferon-beta Treatment and the Combination Therapy with Interferon-alpha Plus Ribavirin

Hirofumi Nakajima, Hiroyuki Shimomura, Yoshiaki Iwasaki, Fusao Ikeda, Fumi Umeoka, Piao Chengyu, Hideaki Taniguchi, Yasuhiro Ohnishi, Shin Jirou Takagi, Shin Ichi Fujioka, Yasushi Shiratori

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To improve the efficacy of interferon (IFN) treatment for chronic hepatitis C, we have proposed the twice-daily administration of IFN-beta as a promising induction therapy. In this study, we demonstrated differences between the clearance of circulating HCV-RNA and the induction of anti-viral actions during the first 2 weeks of treatment. Nine patients with a high viral load and genotype 1b were randomly assigned to 3 groups: group A received 3MU of IFN-beta twice a day at intervals of 5 and 19 h; group B received 3MU of IFN-beta twice a day at intervals of 10 and 14 h; group C received 6MU of IFN-alpha once a day with ribavirin. The expression of OAS2, PKR, and MxA in peripheral blood mononuclear cells (PBMCs) were quantified by real-time polymerase chain reaction method. The viral clearance showed a bi-phasic pattern, and those in the second phase of groups A and B were significantly steeper than that of group C. The peak level of OAS2 during the first phase was correlated with the first phase decay. The MxA expression tended to be higher in group A and B than in group C. The expression of these 3 proteins tended to decrease at day 6 in group C, but increase in groups A and B. These might make differences in the viral decay during the second phase.

Original languageEnglish
Pages (from-to)217-225
Number of pages9
JournalActa Medica Okayama
Volume57
Issue number5
Publication statusPublished - Oct 2003

Fingerprint

Ribavirin
Interferon-beta
Chronic Hepatitis C
Interferon-alpha
Interferons
Polymerase chain reaction
Viral Load
Real-Time Polymerase Chain Reaction
Blood Cells
Blood
Therapeutics
Genotype
RNA
Proteins

Keywords

  • Antiviral actions
  • Chronic hepatitis C (CHC)
  • Hepatitis C virus (HCV) dynamics
  • Interferon (IFN) beta
  • Real time PCR

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Anti-viral Actions and Viral Dynamics in the Early Phase of Three Different Regimens of Interferon Treatment for Chronic Hepatitis C : Differences between the Twice-daily Administration of Interferon-beta Treatment and the Combination Therapy with Interferon-alpha Plus Ribavirin. / Nakajima, Hirofumi; Shimomura, Hiroyuki; Iwasaki, Yoshiaki; Ikeda, Fusao; Umeoka, Fumi; Chengyu, Piao; Taniguchi, Hideaki; Ohnishi, Yasuhiro; Takagi, Shin Jirou; Fujioka, Shin Ichi; Shiratori, Yasushi.

In: Acta Medica Okayama, Vol. 57, No. 5, 10.2003, p. 217-225.

Research output: Contribution to journalArticle

Nakajima, Hirofumi ; Shimomura, Hiroyuki ; Iwasaki, Yoshiaki ; Ikeda, Fusao ; Umeoka, Fumi ; Chengyu, Piao ; Taniguchi, Hideaki ; Ohnishi, Yasuhiro ; Takagi, Shin Jirou ; Fujioka, Shin Ichi ; Shiratori, Yasushi. / Anti-viral Actions and Viral Dynamics in the Early Phase of Three Different Regimens of Interferon Treatment for Chronic Hepatitis C : Differences between the Twice-daily Administration of Interferon-beta Treatment and the Combination Therapy with Interferon-alpha Plus Ribavirin. In: Acta Medica Okayama. 2003 ; Vol. 57, No. 5. pp. 217-225.
@article{475d03db6da7415d9756300d8c391b96,
title = "Anti-viral Actions and Viral Dynamics in the Early Phase of Three Different Regimens of Interferon Treatment for Chronic Hepatitis C: Differences between the Twice-daily Administration of Interferon-beta Treatment and the Combination Therapy with Interferon-alpha Plus Ribavirin",
abstract = "To improve the efficacy of interferon (IFN) treatment for chronic hepatitis C, we have proposed the twice-daily administration of IFN-beta as a promising induction therapy. In this study, we demonstrated differences between the clearance of circulating HCV-RNA and the induction of anti-viral actions during the first 2 weeks of treatment. Nine patients with a high viral load and genotype 1b were randomly assigned to 3 groups: group A received 3MU of IFN-beta twice a day at intervals of 5 and 19 h; group B received 3MU of IFN-beta twice a day at intervals of 10 and 14 h; group C received 6MU of IFN-alpha once a day with ribavirin. The expression of OAS2, PKR, and MxA in peripheral blood mononuclear cells (PBMCs) were quantified by real-time polymerase chain reaction method. The viral clearance showed a bi-phasic pattern, and those in the second phase of groups A and B were significantly steeper than that of group C. The peak level of OAS2 during the first phase was correlated with the first phase decay. The MxA expression tended to be higher in group A and B than in group C. The expression of these 3 proteins tended to decrease at day 6 in group C, but increase in groups A and B. These might make differences in the viral decay during the second phase.",
keywords = "Antiviral actions, Chronic hepatitis C (CHC), Hepatitis C virus (HCV) dynamics, Interferon (IFN) beta, Real time PCR",
author = "Hirofumi Nakajima and Hiroyuki Shimomura and Yoshiaki Iwasaki and Fusao Ikeda and Fumi Umeoka and Piao Chengyu and Hideaki Taniguchi and Yasuhiro Ohnishi and Takagi, {Shin Jirou} and Fujioka, {Shin Ichi} and Yasushi Shiratori",
year = "2003",
month = "10",
language = "English",
volume = "57",
pages = "217--225",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Anti-viral Actions and Viral Dynamics in the Early Phase of Three Different Regimens of Interferon Treatment for Chronic Hepatitis C

T2 - Differences between the Twice-daily Administration of Interferon-beta Treatment and the Combination Therapy with Interferon-alpha Plus Ribavirin

AU - Nakajima, Hirofumi

AU - Shimomura, Hiroyuki

AU - Iwasaki, Yoshiaki

AU - Ikeda, Fusao

AU - Umeoka, Fumi

AU - Chengyu, Piao

AU - Taniguchi, Hideaki

AU - Ohnishi, Yasuhiro

AU - Takagi, Shin Jirou

AU - Fujioka, Shin Ichi

AU - Shiratori, Yasushi

PY - 2003/10

Y1 - 2003/10

N2 - To improve the efficacy of interferon (IFN) treatment for chronic hepatitis C, we have proposed the twice-daily administration of IFN-beta as a promising induction therapy. In this study, we demonstrated differences between the clearance of circulating HCV-RNA and the induction of anti-viral actions during the first 2 weeks of treatment. Nine patients with a high viral load and genotype 1b were randomly assigned to 3 groups: group A received 3MU of IFN-beta twice a day at intervals of 5 and 19 h; group B received 3MU of IFN-beta twice a day at intervals of 10 and 14 h; group C received 6MU of IFN-alpha once a day with ribavirin. The expression of OAS2, PKR, and MxA in peripheral blood mononuclear cells (PBMCs) were quantified by real-time polymerase chain reaction method. The viral clearance showed a bi-phasic pattern, and those in the second phase of groups A and B were significantly steeper than that of group C. The peak level of OAS2 during the first phase was correlated with the first phase decay. The MxA expression tended to be higher in group A and B than in group C. The expression of these 3 proteins tended to decrease at day 6 in group C, but increase in groups A and B. These might make differences in the viral decay during the second phase.

AB - To improve the efficacy of interferon (IFN) treatment for chronic hepatitis C, we have proposed the twice-daily administration of IFN-beta as a promising induction therapy. In this study, we demonstrated differences between the clearance of circulating HCV-RNA and the induction of anti-viral actions during the first 2 weeks of treatment. Nine patients with a high viral load and genotype 1b were randomly assigned to 3 groups: group A received 3MU of IFN-beta twice a day at intervals of 5 and 19 h; group B received 3MU of IFN-beta twice a day at intervals of 10 and 14 h; group C received 6MU of IFN-alpha once a day with ribavirin. The expression of OAS2, PKR, and MxA in peripheral blood mononuclear cells (PBMCs) were quantified by real-time polymerase chain reaction method. The viral clearance showed a bi-phasic pattern, and those in the second phase of groups A and B were significantly steeper than that of group C. The peak level of OAS2 during the first phase was correlated with the first phase decay. The MxA expression tended to be higher in group A and B than in group C. The expression of these 3 proteins tended to decrease at day 6 in group C, but increase in groups A and B. These might make differences in the viral decay during the second phase.

KW - Antiviral actions

KW - Chronic hepatitis C (CHC)

KW - Hepatitis C virus (HCV) dynamics

KW - Interferon (IFN) beta

KW - Real time PCR

UR - http://www.scopus.com/inward/record.url?scp=10744229234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229234&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 217

EP - 225

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -